ClinicalTrials.gg
RecruitingNCT07675265OBSERVE-ARDSUpdated Sep 28, 2026

Observational, Non-interventional Biomarker and Endotyping Study

An observational study in ARDS (Acute Respiratory Distress Syndrome), sponsored by Prenosis, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Prenosis, Inc. · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 28, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.

Planned enrollment
3rd of 22
1,200 · median 135
Started
2026
with 5 others
Observational
23 of 112
4 open now
Primary completion
2028-12
later than 13 of 18 live
Registered
110th of 112
by date

Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 3rd largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2026, is one of 23 observational ones, reaches primary completion later than 13 of the 18 other live ones, and was the 110th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Acute Lung Injury with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to establish a centralized ARDS biorepository of longitudinal biospecimens and harmonized clinical data, develop unsupervised, therapy-agnostic endotyping algorithms, and develop unsupervised, therapy-specific treatment-prediction algorithms over a 24 month period.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with clinically defined acute respiratory distress syndrome (ARDS)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • ARDS Diagnosis (New Global Definition of ARDS)
  • Timing: Acute onset within 7 days
  • Radiology: Bilateral pulmonary opacities
  • Hypoxia:

Non-intubated ARDS: PaO2:FIO2\<300mmHg or SpO2:FIO2\<315 (if SpO2\<97%) on HFNO with flow of >30 L/min or NIV/CPAP with at least 5 cm H2O end-expiratory pressure; or Intubated ARDS: PaO2:FIO2\<300 mm Hg or SpO2:FIO2\<315 (if SpO2\<97%)

  • ICU admission
  • Enrolled within 72 hours of meeting inclusion criteria

Exclusion criteria

Exclusion Criteria:

  • Primary cardiogenic pulmonary edema
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of Participants with an ARDS Diagnosis

    Adults with clinically defined ARDS receiving ICU-level care

    Time frame: from enrollment to 28-day in-hospital mortality

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 46 observational studies under Acute Lung Injury, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 27 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 30, 2026
StartActual
Sep 14, 2026was Jul 2026
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
1 site added — first site in United States
Show site
  • Carle Foundation Hospital · Urbana, United States
Sep 28, 2026
Start date
Jul 2026→Sep 14, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Carle Foundation Hospital · Urbana, United States
    Start date Jul 2026→Sep 14, 2026 (now actual)
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07675265
Lead sponsor
Prenosis, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Sep 14, 2026
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion